AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21360528
Drug: Videoconference (VC)
RxNorm normalized name: phenylephrine hydrochloride / promethazine hydrochloride Oral Solution [Phenergan VC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videoconference (VC) delivery of cognitive-behavioral anger management treatment (AMT)
Trial: 21360528
Drug: In-person delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-person delivery of cognitive-behavioral anger management treatment (AMT)
Trial: 14552179
Drug: D‐panthenol (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐panthenol (5% drops and 5% gel)
Trial: 10468503
Drug: L‐N(G) methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐N(G) methyl arginine hydrochloride (L‐NMMA) 6 mg/kg intravenous infusion
Trial: 10468503
Drug: L‐N(G) methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐N(G) methyl arginine hydrochloride (L‐NMMA)
Trial: 7782110
Drug: amoxycillin 500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxycillin 500 mg/clavulanic acid 125 mg t.i.d.
Trial: 2212255
Drug: Intestinal decontamination
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intestinal decontamination (tobramycin 80 mg and colistin 100 mg, four times daily via gastric tube)
Trial: 27324882
Drug: Spa therapy
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spa therapy plus standard drug treatment
Trial: 365289
Drug: Standard drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drug treatment alone
Trial: 19789937
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser treatment (810-nm, 2 W)
Trial: 9563139
Drug: 1-month depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-month depot (3.75 mg leuprorelin acetate)
Trial: 9563139
Drug: 3-month depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-month depot (11.25 mg leuprorelin acetate)
Trial: 7885968
Drug: Cefepime (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (1-2 g every 8-12 hours)
Trial: 3199913
Drug: Combination clinical/telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination clinical/telephone interventions
Trial: 27686283
Drug: BioNet's aP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BioNet's aP vaccine
Trial: 27686283
Drug: BioNet's TdaP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BioNet's TdaP vaccine
Trial: 27686283
Drug: Adacel® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adacel® vaccine
Trial: 8147095
Drug: All vaccine
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All vaccine groups
Trial: 14681341
Drug: Etoricoxib 120
RxNorm normalized name: etoricoxib 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 120 mg single oral dose
Trial: 7917739
Drug: Ornipressin 10(‐4)
RxNorm normalized name: ornipressin
DrugBank: Ornipressin (DB13464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornipressin 10(‐4) u. ml‐1
Trial: 7917739
Drug: Ornipressin 10(‐2)
RxNorm normalized name: ornipressin
DrugBank: Ornipressin (DB13464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornipressin 10(‐2) u. ml‐1
Trial: 7917739
Drug: Ornipressin 10(‐1)
RxNorm normalized name: ornipressin
DrugBank: Ornipressin (DB13464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornipressin 10(‐1) u. ml‐1
Trial: 7917739
Drug: Ornipressin 10(0)
RxNorm normalized name: ornipressin
DrugBank: Ornipressin (DB13464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornipressin 10(0) u. ml‐1
Trial: 7917739
Drug: Ornipressin 10(‐3)
RxNorm normalized name: ornipressin
DrugBank: Ornipressin (DB13464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornipressin 10(‐3) to 10(‐1) u. ml‐1
Trial: 3293456
Drug: Hydroxyurea (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (80 mg/kg each Monday and Thursday during external radiation therapy)
Trial: 29696684
Drug: Fostamatinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib (100 mg BID for 24 weeks, increased to 150 mg BID for nonresponders after 4 weeks)
Trial: 26653203
Drug: Self-testing (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-testing (4 oral-fluid self-test kits at enrolment, additional kits on request)
Trial: 18192839
Drug: ACEIs (Angiotensin-Converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEIs (Angiotensin-Converting Enzyme Inhibitors) administered for 6 weeks
Trial: 16704648
Drug: Two-compound product
RxNorm normalized name: Ceo-Two Rectal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-compound product (Dovobet/Daivobet/Taclonex) for 52 weeks
Trial: 16704648
Drug: Alternating group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating group (two-compound product and calcipotriol for 52 weeks)
Trial: 16704648
Drug: Calcipotriol for
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol for 48 weeks after 4 weeks of the two-compound product
Trial: 16704648
Drug: Two-compound product
RxNorm normalized name: Ceo-Two Rectal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-compound product vs Calcipotriol
Trial: 16704648
Drug: Two-compound product
RxNorm normalized name: Ceo-Two Rectal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-compound product
Trial: 15581966
Drug: High-dose intraarterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration (PPPEC) using high-dose cisplatin alone (140-250 mg/m2) or high-dose cisplatin plus mitomycin C (7 mg/m2), pepleomycin (7 mg/m2) and 5-fluorouracil (700 mg/m2)
Trial: 10945313
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice with 5 mg felodipine
Trial: 10945313
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice with 2.5 mg felodipine for 2 days followed by 5 mg felodipine for 6 days
Trial: 10945313
Drug: Water with
RxNorm normalized name: sterile water with electrolytes injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water with 5 mg felodipine
Trial: 10945313
Drug: Water with
RxNorm normalized name: sterile water with electrolytes injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water with 2.5 mg felodipine for 2 days followed by 5 mg felodipine for 6 days
Trial: 8405008
Drug: Pravastatin 5
RxNorm normalized name: pravastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 5 mg/day (Group 1)
Trial: 8405008
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg/day (Group 2)
Trial: 8405008
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (both groups)
Trial: 30219475
Drug: Hydroalcoholic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroalcoholic extract of M. officinalis (HEMO) (700 mg/d)
Trial: 25747955
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg omega-3 fatty acid supplements (containing 180 mg eicosapentaenoic acid and 120 mg docosahexanoic acid)
Trial: 25576353
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + chemotherapy
Trial: 10942228
Drug: Low-dose cytarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytarabine (LDAC), 10 mg/m2 subcutaneously twice a day for 21 days every 2 months until relapse.
Trial: 10942228
Drug: Observation (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (no additional therapy).
Trial: 10942228
Drug: Low-dose cytarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytarabine (LDAC).
Trial: 1578935
Drug: Prolonged intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged intensive chemotherapy
Trial: 3922936
Drug: Aztreonam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam (1 or 2 g intramuscular injections for ten days)
Trial: 29193747
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg cherry-flavored mini lozenge
Trial: 29193747
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg cherry-flavored mini lozenge
Trial: 29193747
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg mint-flavored mini lozenge
Trial: 29193747
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg mint-flavored mini lozenge
Trial: 26354927
Drug: Procarbazine/lomustine/vincristine (PCV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procarbazine/lomustine/vincristine (PCV) chemotherapy
Trial: 23761303
Drug: Zoledronate 1
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronate 1 mg
Trial: 23761303
Drug: Zoledronate 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronate 2.5 mg
Trial: 19952950
Drug: Low-dose interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose interferon-alpha 2a
Trial: 16177249
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of azithromycin orally
Trial: 16177249
Drug: 2.4 million
RxNorm normalized name: penicillin G benzathine 2.4 million unit INTRAMUSC VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 million units of penicillin G benzathine intramuscularly
Trial: 11929348
Drug: Salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone propionate combination (SFC) 50/100microg, administered twice daily via inhaler for 12 weeks
Trial: 11929348
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 100microg, administered twice daily via inhaler for 12 weeks
Trial: 28604133
Drug: Topical cetirizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cetirizine 1%
Trial: 26892849
Drug: Eye movement
RxNorm normalized name: JOINT MOVEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye movement desensitisation and reprocessing (EMDR) therapy (12 hours total: 3×60 min planning/preparation followed by 6×90 min desensitisation/reprocessing)
Trial: 26892849
Drug: Stabilisation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stabilisation therapy (12 hours total: 12×60 min)
Trial: 23842081
Drug: Milk-fat from
RxNorm normalized name: MILK FAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk-fat from mountain-pasture grazing cows (G)
Trial: 21731996
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine with midazolam (3 mL 0.5% bupivacaine and 0.4 mL (2 mg) midazolam)
Trial: 21731996
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine without midazolam (3 mL 0.5% bupivacaine with 0.4 mL saline)
Trial: 19362014
Drug: Cohen blocker
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohen blocker
Trial: 19499865
Drug: Arndt blocker
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arndt blocker
Trial: 19362014
Drug: Cohen blocker
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohen blocker (left bronchus occlusion)
Trial: 19362014
Drug: Cohen blocker
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohen blocker (right bronchus occlusion)
Trial: 19362014
Drug: All blockers
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All blockers
Trial: 19362014
Drug: Cohen blocker
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohen blocker and Arndt blocker
Trial: 17081282
Drug: Intravenous trace
RxNorm normalized name: Trace metal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trace element supplements (copper 2.5 to 3.1 mg/day, selenium 315 to 380 µg/day, zinc 26.2 to 31.4 mg/day) for 8 to 21 days
Trial: 17081282
Drug: Intravenous trace
RxNorm normalized name: Trace metal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trace element supplements
Trial: 15471833
Drug: 99mTc‐labeled ethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc‐labeled ethylene dicysteine (EC) C225 administered before 20 mg test dose
Trial: 15471833
Drug: 99mTc‐labeled ethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc‐labeled ethylene dicysteine (EC) C225 administered after 400 mg/m2 loading dose of unlabeled C225
Trial: 9266270
Drug: Ampicillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (1 g)/Sulbactam (0.5 g)
Trial: 9266270
Drug: Cefotiam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotiam (2 g)
Trial: 8119065
Drug: Diet treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet treatment (control-assigned group)
Trial: 6480455
Drug: Dexamethasone (DEXA)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEXA) 2 mg t.i.d. during treatment
Trial: 30125052
Drug: Epanova 4
RxNorm normalized name: Epanova
DrugBank: Omega-3-carboxylic acids (DB09568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epanova 4 g daily
Trial: 19552598
Drug: Xuezhikang (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang (1200 mg/d)
Trial: 15048162
Drug: Early goal
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early goal directed therapy
Trial: 15048162
Drug: Moderate doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate doses of steroids
Trial: 8725851
Drug: Miglitol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol (50 mg three times daily)
Trial: 1340780
Drug: Ephedrine 50
RxNorm normalized name: Ephedrine 50 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 50 mg
Trial: 498825
Drug: Ephedrine 25
RxNorm normalized name: ephedrine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 25 mg
Trial: 6726466
Drug: Maternal pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal pyridoxine X HCl (PN‐HCl) supplementation at 7.5 mg or more
Trial: 6726466
Drug: Maternal pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal pyridoxine X HCl (PN‐HCl) supplementation at 7.5 mg and greater
Trial: 6726466
Drug: Maternal pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal pyridoxine X HCl (PN‐HCl) supplementation at 7.5 mg
Trial: 6726466
Drug: Vitamin B-6
RxNorm normalized name: Vitamin B-6 100mg Tablet
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B-6 intake between 5.5 and 7.6 mg/day (diet plus supplement as pyridoxine equivalents)
Trial: 19332958
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg plus amlodipine 10 mg
Trial: 19332958
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg (monotherapy)
Trial: 19332958
Drug: Telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg plus amlodipine 10 mg
Trial: 16537682
Drug: saline/ghrelin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline/ghrelin infusion
Trial: 16537682
Drug: l-arginine/saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine/saline
Trial: 16537682
Drug: l-arginine/ghrelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine/ghrelin
Trial: 12683264
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (except amisulpride)
Trial: 8622332
Drug: Alpha-tocopherol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-tocopherol (800 IU daily for first 546 patients; 400 IU daily for remainder)
Trial: 1391111
Drug: Conventional diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diet administered to 21 patients
Trial: 1391111
Drug: Commercial enteral
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial enteral diet administered to 28 patients
Trial: 6399448
Drug: General treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General treatment program for alcoholism including relaxation training
Trial: 24568148
Drug: Myoelectric simulator
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myoelectric simulator training (combination of tasks)
Trial: 22321357
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel (Continuing Active subjects)
Trial: 22321357
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel (Formerly Placebo subjects)
Trial: 18004138
Drug: Venlafaxine 37.5
RxNorm normalized name: venlafaxine 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 37.5 mg BID for 7 days followed by 75 mg BID for another 7 days
Trial: 9744643
Drug: rBPI21 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rBPI21 administered by continuous intravenous infusion for 48 hours in patients and healthy volunteers
Trial: 9744643
Drug: rBPI21 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rBPI21 administered intravenously in rats after 60% or 80% hepatectomy
Trial: 9744643
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered to healthy volunteers
Trial: 3054591
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with preoperative radiotherapy (4 Gy for 5 days, total 20 Gy)
Trial: 3054591
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with preoperative radiotherapy
Trial: 28500492
Drug: Methylprednisolone 500
RxNorm normalized name: methylprednisolone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 500 mg i.v.
Trial: 28500492
Drug: Paracetamol 4
RxNorm normalized name: Paracetamol 48.2 mg/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 4 g i.v.
Trial: 28500492
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Methylprednisolone, Paracetamol, Placebo)
Trial: 26135245
Drug: Investigational MenABCWY
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational MenABCWY vaccine formulations (2 doses)
Trial: 26135245
Drug: Investigational MenABCWY
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational MenABCWY vaccine formulations (3 doses)
Trial: 26135245
Drug: Investigational MenABCWY
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational MenABCWY vaccines (2 or 3 doses)
Trial: 26135245
Drug: Investigational MenABCWY
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational MenABCWY vaccines
Trial: 21452294
Drug: Atacicept 150
RxNorm normalized name: Atacicept
DrugBank: Atacicept (DB06399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept 150 mg weekly (with or without a 4-week loading period)
Trial: 12900133
Drug: High-dose magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose magnesium and low-dose lidocaine, infused over 3 days
Trial: 10875098
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (ampicillin)
Trial: 7956612
Drug: Propranolol (30-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (30-60 mg/day)
Trial: 2852692
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MCP) 10 mg iv
Trial: 2852692
Drug: Domperidone (DMP)
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (DMP) 10 mg iv
Trial: 27567243
Drug: Intravenous glyburide
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glyburide
Trial: 27537707
Drug: Non-Hoarding Community
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Hoarding Community Controls (CC)